Mara Dierssen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7589887/publications.pdf

Version: 2024-02-01

187	9,883	31976	46799
papers	citations	53 h-index	89 g-index

209	209	209	10452
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurology, The, 2010, 9, 623-633.	10.2	372
2	Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. Human Molecular Genetics, 2001, 10, 1915-1923.	2.9	357
3	Dyrk1A Haploinsufficiency Affects Viability and Causes Developmental Delay and Abnormal Brain Morphology in Mice. Molecular and Cellular Biology, 2002, 22, 6636-6647.	2.3	306
4	Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. Neuron, 2013, 79, 1152-1168.	8.1	254
5	Epigallocatechinâ€3â€gallate, a DYRK1A inhibitor, rescues cognitive deficits in <scp>D</scp>own syndrome mouse models and in humans. Molecular Nutrition and Food Research, 2014, 58, 278-288.	3.3	234
6	A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neuroscience Letters, 1995, 199, 143-146.	2.1	233
7	Down syndrome: the brain in trisomic mode. Nature Reviews Neuroscience, 2012, 13, 844-858.	10.2	230
8	Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 801-810.	10.2	227
9	Fibrinogen drives dystrophic muscle fibrosis via a TGFÎ²/alternative macrophage activation pathway. Genes and Development, 2008, 22, 1747-1752.	5.9	222
10	Understanding the human brain through mouse models. Genes, Brain and Behavior, 2007, 6, 1-1.	2.2	203
11	Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nature Medicine, 2013, 19, 603-607.	30.7	203
12	Potential Role of Olive Oil Phenolic Compounds in the Prevention of Neurodegenerative Diseases. Molecules, 2015, 20, 4655-4680.	3.8	181
13	Dendritic pathology in mental retardation: from molecular genetics to neurobiology. Genes, Brain and Behavior, 2006, 5, 48-60.	2.2	166
14	Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome. Behavioural Brain Research, 2002, 134, 185-200.	2.2	156
15	Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3136-45.	7.1	155
16	Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiology of Disease, 2005, 20, 392-400.	4.4	152
17	Impaired short- and long-term memory in Ts65Dn mice, a model for Down syndrome. Neuroscience Letters, 1998, 247, 171-174.	2.1	149
18	Hippocampal volume and neuronal number in Ts65Dn mice: a murine model of down syndrome. Neuroscience Letters, 1998, 253, 175-178.	2.1	137

#	Article	IF	Citations
19	Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns. Translational Psychiatry, 2016, 6, e718-e718.	4.8	137
20	Alterations of Neocortical Pyramidal Cell Phenotype in the Ts65Dn Mouse Model of Down Syndrome: Effects of Environmental Enrichment. Cerebral Cortex, 2003, 13, 758-764.	2.9	136
21	Down Syndrome: From Understanding the Neurobiology to Therapy. Journal of Neuroscience, 2010, 30, 14943-14945.	3.6	133
22	DNA methylation map of mouse and human brain identifies target genes in Alzheimerâ€™s disease. Brain, 2013, 136, 3018-3027.	7.6	129
23	Dyrk1A expression pattern supports specific roles of this kinase in the adult central nervous system. Brain Research, 2003, 964, 250-263.	2.2	125
24	On dendrites in Down syndrome and DS murine models: a spiny way to learn. Progress in Neurobiology, 2004, 74, 111-126.	5.7	124
25	Synaptic deficit in the temporal cortex of partial trisomy 16 (Ts65Dn) mice. Brain Research, 2000, 858, 191-197.	2.2	115
26	Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Research, 2004, 1022, 101-109.	2.2	108
27	Aneuploidy: From a Physiological Mechanism of Variance to Down Syndrome. Physiological Reviews, 2009, 89, 887-920.	28.8	106
28	Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage. Neurobiology of Disease, 2014, 69, 65-75.	4.4	104
29	Fetal Down Syndrome Brains Exhibit Aberrant Levels of Neurotransmitters Critical for Normal Brain Development. Pediatrics, 2007, 120, e1465-e1471.	2.1	101
30	A new mouse model for the trisomy of the Abcg1â€“U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome. Human Molecular Genetics, 2009, 18, 4756-4769.	2.9	101
31	Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: Involvement of phospholipaseCÎ³ activity and glutamate receptor expression. Neuroscience, 2009, 158, 1234-1250.	2.3	98
32	Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome. Brain Research, 1997, 749, 238-244.	2.2	97
33	Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/â^' mouse. Neurobiology of Disease, 2005, 20, 115-122.	4.4	94
34	Impaired Spatial Learning Strategies and Novel Object Recognition in Mice Haploinsufficient for the Dual Specificity Tyrosine-Regulated Kinase-1A (Dyrk1A). PLoS ONE, 2008, 3, e2575.	2.5	87
35	Overexpression of Reelin Prevents the Manifestation of Behavioral Phenotypes Related to Schizophrenia and Bipolar Disorder. Neuropsychopharmacology, 2011, 36, 2395-2405.	5.4	85
36	Dyrk1A Influences Neuronal Morphogenesis Through Regulation of Cytoskeletal Dynamics in Mammalian Cortical Neurons. Cerebral Cortex, 2012, 22, 2867-2877.	2.9	84

#	Article	IF	Citations
37	DYRK1A (Dual-Specificity Tyrosine-Phosphorylated and -Regulated Kinase 1A): A Gene with Dosage Effect During Development and Neurogenesis. Scientific World Journal, The, 2006, 6, 1911-1922.	2.1	81
38	The Mouse Brain Transcriptome by SAGE: Differences in Gene Expression between P30 Brains of the Partial Trisomy 16 Mouse Model of Down Syndrome (Ts65Dn) and Normals. Genome Research, 2000, 10, 2006-2021.	5.5	81
39	Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids, 2008, 35, 339-343.	2.7	77
40	Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction. Neurobiology of Disease, 2004, 15, 132-142.	4.4	75
41	Medical vulnerability of individuals with Down syndrome to severe COVID-19â€“data from the Trisomy 21 Research Society and the UK ISARIC4C survey. EClinicalMedicine, 2021, 33, 100769.	7.1	73
42	Ceramide Levels Regulated by Carnitine Palmitoyltransferase 1C Control Dendritic Spine Maturation and Cognition. Journal of Biological Chemistry, 2012, 287, 21224-21232.	3.4	71
43	A specific prelimbic-nucleus accumbens pathway controls resilience versus vulnerability to food addiction. Nature Communications, 2020, 11, 782.	12.8	70
44	Heterozygous deletion of the Williamsâ€“Beuren syndrome critical interval in mice recapitulates most features of the human disorder. Human Molecular Genetics, 2014, 23, 6481-6494.	2.9	69
45	Proteomic analysis of the fetal brain. Proteomics, 2002, 2, 1547-1576.	2.2	68
46	Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease, 2013, 52, 117-127.	4.4	67
47	uPA deficiency exacerbates muscular dystrophy in MDX mice. Journal of Cell Biology, 2007, 178, 1039-1051.	5.2	66
48	Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. Neurobiology of Disease, 2013, 60, 18-31.	4.4	66
49	Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome. Cortex, 2015, 64, 148-156.	2.4	64
50	RESEARCH FOCUS ON COMPULSIVE BEHAVIOUR IN ANIMALS: An animal model of compulsive foodâ€taking behaviour. Addiction Biology, 2009, 14, 373-383.	2.6	63
51	Murine models for Down syndrome. Physiology and Behavior, 2001, 73, 859-871.	2.1	62
52	Haploinsufficiency of Dyrk1A in Mice Leads to Specific Alterations in the Development and Regulation of Motor Activity.. Behavioral Neuroscience, 2004, 118, 815-821.	1.2	61
53	Early Environmental Stimulation Produces Long-Lasting Changes on Î²-Adrenoceptor Transduction System. Neurobiology of Learning and Memory, 1995, 64, 49-57.	1.9	60
54	Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome. American Journal of Human Genetics, 2008, 83, 479-488.	6.2	60

#	Article	IF	Citations
55	A murine model for Down syndrome shows reduced responsiveness to pain. NeuroReport, 1999, 10, 1119-1122.	1.2	56
56	Overexpression ofDyrk1A, a Down Syndrome Candidate, Decreases Excitability and Impairs Gamma Oscillations in the Prefrontal Cortex. Journal of Neuroscience, 2016, 36, 3648-3659.	3.6	54
57	Calcium channel modulation by dihydropyridines modifies sufentanil-induced antinociception in acute and tolerant conditions. Naunyn-Schmiedeberg's Archives of Pharmacology, 1990, 342, 559-65.	3.0	53
58	Î²-amyloid controls altered Reelin expression and processing in Alzheimer's disease. Neurobiology of Disease, 2010, 37, 682-691.	4.4	53
59	Therapeutic approaches in the improvement of cognitive performance in Down syndrome. Progress in Brain Research, 2012, 197, 1-14.	1.4	53
60	A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials. Frontiers in Psychology, 2015, 6, 708.	2.1	53
61	Potential Role of (-)-Epigallocatechin-3-Gallate (EGCG) in the Secondary Prevention of Alzheimer Disease. Current Drug Targets, 2016, 18, 174-195.	2.1	51
62	Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. Neurobiology of Disease, 2006, 24, 403-418.	4.4	50
63	Association of NTRK3 and its interaction with NGF suggest an altered cross-regulation of the neurotrophin signaling pathway in eating disorders. Human Molecular Genetics, 2008, 17, 1234-1244.	2.9	50
64	Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations. Neurobiology of Disease, 2010, 40, 348-359.	4.4	49
65	Impaired cyclic AMP production in the hippocampus of a Down syndrome murine model. Developmental Brain Research, 1996, 95, 122-124.	1.7	48
66	Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions. Frontiers in Neuroscience, 2020, 14, 670.	2.8	48
67	Neurobehavioral development of two mouse lines commonly used in transgenic studies. Pharmacology Biochemistry and Behavior, 2002, 73, 19-25.	2.9	46
68	Prefrontalâ€“hippocampal functional connectivity encodes recognition memory and is impaired in intellectual disability. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 11788-11798.	7.1	45
69	Dissociation between CA3-CA1 Synaptic Plasticity and Associative Learning in TgNTRK3 Transgenic Mice. Journal of Neuroscience, 2007, 27, 2253-2260.	3.6	44
70	Principal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down Syndrome. Frontiers in Behavioral Neuroscience, 2015, 9, 330.	2.0	44
71	Behavioral Characterization of a Mouse Model Overexpressing DSCR1/ RCAN1. PLoS ONE, 2011, 6, e17010.	2.5	42
72	Combined Treatment With Environmental Enrichment and (-)-Epigallocatechin-3-Gallate Ameliorates Learning Deficits and Hippocampal Alterations in a Mouse Model of Down Syndrome. ENeuro, 2016, 3, ENEURO.0103-16.2016.	1.9	42

#	Article	IF	Citations
73	Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome. Neurobiology of Disease, 2008, 32, 377-384.	4.4	41
74	DREAM Controls the On/Off Switch of Specific Activity-Dependent Transcription Pathways. Molecular and Cellular Biology, 2014, 34, 877-887.	2.3	41
75	Monoamine deficits in the brain of methyl-CpG binding protein 2 null mice suggest the involvement of the cerebral cortex in early stages of Rett syndrome. Neuroscience, 2010, 170, 453-467.	2.3	40
76	RhoE Deficiency Produces Postnatal Lethality, Profound Motor Deficits and Neurodevelopmental Delay in Mice. PLoS ONE, 2011, 6, e19236.	2.5	39
77	Opposite Phenotypes of Muscle Strength and Locomotor Function in Mouse Models of Partial Trisomy and Monosomy 21 for the Proximal Hspa13-App Region. PLoS Genetics, 2015, 11, e1005062.	3.5	39
78	Carnitine palmitoyltransferase 1C deficiency causes motor impairment and hypoactivity. Behavioural Brain Research, 2013, 256, 291-297.	2.2	38
79	Mutations in L-type amino acid transporter-2 support SLC7A8 as a novel gene involved in age-related hearing loss. ELife, 2018, 7, .	6.0	38
80	Overexpression of the CHRNA5/A3/B4 genomic cluster in mice increases the sensitivity to nicotine and modifies its reinforcing effects. Amino Acids, 2012, 43, 897-909.	2.7	36
81	Loss of ‹scp›SIRT‹/scp›2 leads to axonal degeneration and locomotor disability associated with redox and energy imbalance. Aging Cell, 2017, 16, 1404-1413.	6.7	36
82	Network analysis of Down syndrome and SARS-CoV-2 identifies risk and protective factors for COVID-19. Scientific Reports, 2021, 11, 1930.	3.3	35
83	The Î±3Î²4* nicotinic ‹scp›ACh‹/scp› receptor subtype mediates physical dependence to morphine: mouse and human studies. British Journal of Pharmacology, 2014, 171, 3845-3857.	5.4	34
84	Anomalous White Matter Structure and the Effect of Age in Down Syndrome Patients. Journal of Alzheimer's Disease, 2017, 57, 61-70.	2.6	32
85	Transgenic over expression of nicotinic receptor alpha 5, alpha 3, and beta 4 subunit genes reduces ethanol intake in mice. Alcohol, 2012, 46, 205-215.	1.7	30
86	Hippocampal Hyperexcitability Underlies Enhanced Fear Memories in Tg‹i›NTRK3‹/i›, a Panic Disorder Mouse Model. Journal of Neuroscience, 2013, 33, 15259-15271.	3.6	30
87	Genome-wide miR-155 and miR-802 target gene identification in the hippocampus of Ts65Dn Down syndrome mouse model by miRNA sponges. BMC Genomics, 2015, 16, 907.	2.8	30
88	Specific Susceptibility to COVID-19 in Adults with Down Syndrome. NeuroMolecular Medicine, 2021, 23, 561-571.	3.4	30
89	Cholinergic, serotonergic and catecholaminergic neurons are not affected in Ts65Dn mice. NeuroReport, 1997, 8, 3475-3478.	1.2	29
90	Synthesis and evaluation of tacrine-related compounds for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 1994, 29, 205-221.	5.5	28

#	Article	IF	Citations
91	New Perspectives for the Rescue of Cognitive Disability in Down Syndrome. Journal of Neuroscience, 2015, 35, 13843-13852.	3.6	28
92	Dyrk1A Is Dynamically Expressed on Subsets of Motor Neurons and in the Neuromuscular Junction: Possible Role in Down Syndrome. PLoS ONE, 2013, 8, e54285.	2.5	26
93	Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome. Neurobiology of Disease, 2019, 125, 92-106.	4.4	26
94	Immune Dysregulation and the Increased Risk of Complications and Mortality Following Respiratory Tract Infections in Adults With Down Syndrome. Frontiers in Immunology, 2021, 12, 621440.	4.8	26
95	Dopaminergic deficiency in mice with reduced levels of the dual-specificity tyrosine-phosphorylated and regulated kinase 1A, Dyrk1A+/?. Genes, Brain and Behavior, 2007, 6, 569-578.	2.2	25
96	Candidate genes for panic disorder: insight from human and mouse genetic studies. Genes, Brain and Behavior, 2007, 6, 2-23.	2.2	25
97	A gel-based proteomic method reveals several protein pathway abnormalities in fetal Down syndrome brain. Journal of Proteomics, 2011, 74, 547-557.	2.4	25
98	The role of nicotinic receptors in shaping and functioning of the glutamatergic system: A window into cognitive pathology. Neuroscience and Biobehavioral Reviews, 2014, 46, 315-325.	6.1	25
99	Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice. Neurobiology of Disease, 2009, 36, 312-319.	4.4	24
100	In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model. Amino Acids, 2010, 39, 1571-1580.	2.7	24
101	COVID-19 in Children with Down Syndrome: Data from the Trisomy 21 Research Society Survey. Journal of Clinical Medicine, 2021, 10, 5125.	2.4	24
102	Characterization of a mouse model overexpressing betaâ€site APPâ€cleaving enzyme 2 reveals a new role for BACE2. Genes, Brain and Behavior, 2010, 9, 160-172.	2.2	23
103	Semantic Verbal Fluency Pattern, Dementia Rating Scores and Adaptive Behavior Correlate With Plasma Aî²42 Concentrations in Down Syndrome Young Adults. Frontiers in Behavioral Neuroscience, 2015, 9, 301.	2.0	23
104	New murine Niemann-Pick type C models bearing a pseudoexon-generating mutation recapitulate the main neurobehavioural and molecular features of the disease. Scientific Reports, 2017, 7, 41931.	3.3	23
105	Effect of epigallocatechin gallate on the body composition and lipid profile of down syndrome individuals: Implications for clinical management. Clinical Nutrition, 2020, 39, 1292-1300.	5.0	23
106	Hypothalamus transcriptome profile suggests an anorexia-cachexia syndrome in the anx/anx mouse model. Physiological Genomics, 2008, 35, 341-350.	2.3	22
107	Increased levels of inflammatory plasma markers and obesity risk in a mouse model of Down syndrome. Free Radical Biology and Medicine, 2018, 114, 122-130.	2.9	21
108	DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment. Frontiers in Molecular Neuroscience, 2019, 12, 272.	2.9	21

#	Article	IF	Citations
109	Metabolomics predicts the pharmacological profile of new psychoactive substances. Journal of Psychopharmacology, 2019, 33, 347-354.	4.0	21
110	Reduced phospholipase Câ€Î² activity and isoform expression in the cerebellum of TS65DN mouse: A model of down syndrome. Journal of Neuroscience Research, 2001, 66, 540-550.	2.9	19
111	G-Protein-Associated Signal Transduction Processes Are Restored after Postweaning Environmental Enrichment in Ts65Dn, a Down Syndrome Mouse Model. Developmental Neuroscience, 2011, 33, 442-450.	2.0	19
112	Brain G protein-dependent signaling pathways in Down syndrome and Alzheimerâ€™s disease. Amino Acids, 2006, 31, 449-456.	2.7	18
113	Susceptibility to stress in transgenic mice overexpressing TrkC, a model of panic disorder. Journal of Psychiatric Research, 2010, 44, 157-167.	3.1	18
114	Cognition and Hippocampal Plasticity in the Mouse Is Altered by Monosomy of a Genomic Region Implicated in Down Syndrome. Genetics, 2014, 197, 899-912.	2.9	18
115	Where Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability Disorders. Neural Plasticity, 2016, 2016, 1-20.	2.2	18
116	Pitfalls And Hopes in Down Syndrome Therapeutic Approaches: In the Search for Evidence-Based Treatments. Behavior Genetics, 2006, 36, 454-468.	2.1	17
117	Developmental molecular and functional cerebellar alterations induced by PCP4/PEP19 overexpression: Implications for Down syndrome. Neurobiology of Disease, 2014, 63, 92-106.	4.4	17
118	Changing Paradigms in Down Syndrome: The First International Conference of the Trisomy 21 Research Society. Molecular Syndromology, 2016, 7, 251-261.	0.8	16
119	A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome. Clinical Nutrition, 2020, 39, 378-387.	5.0	16
120	Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with FontupÂ® Dietary Supplement: Role of Green Tea Catechins. International Journal of Molecular Sciences, 2020, 21, 1404.	4.1	16
121	Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome. Progress in Brain Research, 2020, 251, 245-268.	1.4	16
122	Reduced Mid1 Expression and Delayed Neuromotor Development in daDREAM Transgenic Mice. Frontiers in Molecular Neuroscience, 2012, 5, 58.	2.9	15
123	<scp>AGC</scp>1â€malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway. Journal of Neurochemistry, 2013, 124, 347-362.	3.9	15
124	NGF Upregulates the Plasminogen Activation Inhibitor-1 in Neurons via the Calcineurin/NFAT Pathway and the Down Syndrome-Related Proteins DYRK1A and RCAN1 Attenuate This Effect. PLoS ONE, 2013, 8, e67470.	2.5	15
125	Re-establishment of the epigenetic state and rescue of kinome deregulation in Ts65Dn mice upon treatment with green tea extract and environmental enrichment. Scientific Reports, 2020, 10, 16023.	3.3	15
126	Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome. Scientific Reports, 2021, 11, 4715.	3.3	15

#	Article	IF	Citations
127	Potentiation of acute opioid-induced respiratory depression and reversal of tolerance by the calcium antagonist nimodipine in awake rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 348, 633-637.	3.0	14
128	From neural to genetic substrates of panic disorder: Insights from human and mouse studies. European Journal of Pharmacology, 2015, 759, 127-141.	3.5	14
129	Translating molecular advances in Down syndrome and Fragile X syndrome into therapies. European Neuropsychopharmacology, 2018, 28, 675-690.	0.7	14
130	Respiratory actions induced by cholecystokinin at the brainstem level. Peptides, 1988, 9, 809-815.	2.4	13
131	Ca2+ channel modulation by dihydropyridines modifies sufentanil-induced respiratory depression in cats. European Journal of Pharmacology, 1991, 198, 149-155.	3.5	13
132	Differential responses to anxiogenic drugs in a mouse model of panic disorder as revealed by Fos immunocytochemistry in specific areas of the fear circuitry. Amino Acids, 2007, 33, 677-688.	2.7	13
133	Functional implications of hippocampal adult neurogenesis in intellectual disabilities. Amino Acids, 2013, 45, 113-131.	2.7	13
134	Infralimbic Neurotrophin-3 Infusion Rescues Fear Extinction Impairment in a Mouse Model of Pathological Fear. Neuropsychopharmacology, 2017, 42, 462-472.	5.4	13
135	Timeâ€course and dynamics of obesityâ€related behavioral changes induced by energyâ€dense foods in mice. Addiction Biology, 2018, 23, 531-543.	2.6	13
136	Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome. Progress in Brain Research, 2020, 251, 269-302.	1.4	13
137	Meta-analysis of transcriptomic data reveals clusters of consistently deregulated gene and disease ontologies in Down syndrome. PLoS Computational Biology, 2021, 17, e1009317.	3.2	13
138	The Mouse Brain Transcriptome by SAGE: Differences in Gene Expression between P30 Brains of the Partial Trisomy 16 Mouse Model of Down Syndrome (Ts65Dn) and Normals. Genome Research, 2000, 10, 2006-2021.	5.5	13
139	Overexpression of Î±3/Î±5/Î²4 nicotinic receptor subunits modifies impulsive-like behavior. Drug and Alcohol Dependence, 2012, 122, 247-252.	3.2	12
140	Aberrant brain microRNA target and miRISC gene expression in the anx/anx anorexia mouse model. Gene, 2012, 497, 181-190.	2.2	12
141	The Value of Mouse Models of Rare Diseases: A Spanish Experience. Frontiers in Genetics, 2020, 11, 583932.	2.3	12
142	Environmental Enrichment Induces Epigenomic and Genome Organization Changes Relevant for Cognition. Frontiers in Molecular Neuroscience, 2021, 14, 664912.	2.9	12
143	Extinction and reinstatement of an operant responding maintained by food in different models of obesity. Addiction Biology, 2018, 23, 544-555.	2.6	11
144	Post-train administration of 9-amino-1,2,3,4-tetrahydroacridine enhances passive avoidance retention and decreases Î²-adrenoceptor-linked cyclic AMP formation in middle-aged rats. Brain Research, 1992, 586, 117-120.	2.2	10

#	Article	IF	Citations
145	Increased opioid dependence in a mouse model of panic disorder. Frontiers in Behavioral Neuroscience, 2009, 3, 60.	2.0	10
146	RhoE deficiency alters postnatal subventricular zone development and the number of calbindin-expressing neurons in the olfactory bulb of mouse. Brain Structure and Function, 2015, 220, 3113-3130.	2.3	10
147	VNTR-DAT1 and COMTVal158Met Genotypes Modulate Mental Flexibility and Adaptive Behavior Skills in Down Syndrome. Frontiers in Behavioral Neuroscience, 2016, 10, 193.	2.0	10
148	Rethinking Intellectual Disability from Neuro- to Astro-Pathology. International Journal of Molecular Sciences, 2020, 21, 9039.	4.1	10
149	Postnatal Handling Induces Long-term Modifications in Central Î²-noradrenergic Signalling in Rats. Stress, 2002, 5, 137-147.	1.8	9
150	Lamivudine, a reverse transcriptase inhibitor, rescues cognitive deficits in a mouse model of down syndrome. Journal of Cellular and Molecular Medicine, 2022, 26, 4210-4215.	3.6	9
151	Effects of age on Î±1-adrenoceptor subtypes in the heart ventricular muscle of the rat. Journal of Pharmacy and Pharmacology, 2011, 45, 907-909.	2.4	8
152	Reduced cortical neurotransmitter receptor complex levels in fetal Down syndrome brain. Amino Acids, 2016, 48, 103-116.	2.7	8
153	Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society. Molecular Syndromology, 2018, 9, 279-286.	0.8	8
154	Behavioral Phenotyping for Down Syndrome in Mice. Current Protocols in Mouse Biology, 2020, 10, e79.	1.2	8
155	Effects of COVID-19 Home Confinement on Mental Health in Individuals with Increased Risk of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 79, 1015-1021.	2.6	8
156	Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome. CNS and Neurological Disorders - Drug Targets, 2010, 9, 429-438.	1.4	8
157	COVID-19 Vaccination of Individuals with Down Syndromeâ€"Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated. Vaccines, 2022, 10, 530.	4.4	8
158	Mechanism of the respiratory action of pentobarbital at the medullary and pontine levels. European Journal of Pharmacology, 1986, 125, 225-232.	3.5	7
159	Long-Chain Polyunsaturated Fatty Acids in Rat Maternal Milk, Offspring Brain and Peripheral Tissues in Essential Fatty Acid Deficiency. Clinical Chemistry and Laboratory Medicine, 2002, 40, 278-84.	2.3	7
160	Comparison of COVID-19 and Non-COVID-19 Pneumonia in Down Syndrome. Journal of Clinical Medicine, 2021, 10, 3748.	2.4	7
161	Social Factors Influence Behavior in the Novel Object Recognition Task in a Mouse Model of Down Syndrome. Frontiers in Behavioral Neuroscience, 2021, 15, 772734.	2.0	7
162	The Ca2+ channel agonist Bay K 8644 induces central respiratory depression in cats, an effect blocked by naloxone. European Journal of Pharmacology, 1993, 240, 155-161.	3.5	6

#	Article	IF	Citations
163	Hippocampal changes produced by overexpression of the human CHRNA5/A3/B4 gene cluster may underlie cognitive deficits rescued by nicotine in transgenic mice. Acta Neuropathologica Communications, 2014, 2, 147.	5.2	6
164	Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society. Molecular Syndromology, 2021, 12, 202-218.	0.8	6
165	Acute effects of tetrahydroaminoacridine on Î²-adrenoceptor-linked cyclic AMP accumulation in brain of young and middle-aged rats. Neuroscience Letters, 1991, 132, 51-54.	2.1	5
166	Special interest section - Down's syndrome: postgenomic approaches to neurobiological problems. Genes, Brain and Behavior, 2003, 2, 152-155.	2.2	5
167	Pergola: Boosting Visualization and Analysis of Longitudinal Data by Unlocking Genomic Analysis Tools. IScience, 2018, 9, 244-257.	4.1	5
168	Lessons from individuals with Down syndrome during COVID-19. Lancet Neurology, The, 2020, 19, 974-975.	10.2	5
169	Differential effects of physostigmine and 1,2,3,4-tetrahydro-9-aminoacridine on the ÃŸ-adrenoceptor transduction system. European Journal of Pharmacology, 1993, 245, 9-13.	2.6	4
170	ViceCT and whiceCT for simultaneous high-resolution visualization of craniofacial, brain and ventricular anatomy from micro-computed tomography. Scientific Reports, 2020, 10, 18772.	3.3	4
171	Editorial: Brain Insulin Resistance in Neurodevelopmental and Neurodegenerative Disorders: Mind the Gap!. Frontiers in Neuroscience, 2021, 15, 730378.	2.8	4
172	Multimodal in vivo Imaging of the Integrated Postnatal Development of Brain and Skull and Its Co-modulation With Neurodevelopment in a Down Syndrome Mouse Model. Frontiers in Medicine, 2022, 9, 815739.	2.6	4
173	Action on noradrenergic transmission of an anticholinesterase: 9-amino-1,2,3,4-tetrahydroacridine. Neuropharmacology, 1995, 34, 367-375.	4.1	3
174	A cluster of protein kinases and phosphatases modulated in fetal Down syndrome (trisomy 21) brain. Amino Acids, 2015, 47, 1127-1134.	2.7	3
175	Ethanol-Induced Changes in Brain of Transgenic Mice Overexpressing DYRK1A. Molecular Neurobiology, 2020, 57, 3195-3205.	4.0	3
176	MÃ¼ller glia fused with adult stem cells undergo neural differentiation in human retinal models. EBioMedicine, 2022, 77, 103914.	6.1	3
177	Computational Models. , 2018, , 105-131.		2
178	Pergola-web: a web server for the visualization and analysis of longitudinal behavioral data using repurposed genomics tools and standards. Nucleic Acids Research, 2019, 47, W600-W604.	14.5	2
179	Chapter 5.9 Modelling Down syndrome in mice. Handbook of Behavioral Neuroscience, 1999, 13, 895-913.	0.0	1
180	uPA deficiency exacerbates muscular dystrophy in MDX mice. Journal of Cell Biology, 2007, 179, 165-165.	5.2	1

#	Article	IF	Citations
181	Overweight Mice Show Coordinated Homeostatic and Hedonic Transcriptional Response across Brain. ENeuro, 2018, 5, ENEURO.0287-18.2018.	1.9	1
182	Protocol for Measuring Compulsive-like Feeding Behavior in Mice. Bio-protocol, 2019, 9, e3308.	0.4	1
183	Preface. Progress in Brain Research, 2012, 197, vii.	1.4	0
184	A commentary on: Overexpression of Dyrk1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome. Experimental Neurology, 2013, 247, 110-112.	4.1	0
185	Neuroprotective Properties of Wine. , 2018, , 271-284.		0
186	Altered Genetic Expression Disrupts Facial Ontogenetic Trajectory in Down Syndrome and DYRK1A Haploinsufficiency. FASEB Journal, 2021, 35, .	0.5	0
187	Neuropathology and Synaptic Alterations in Neurodevelopmental Disorders. , 2013, , 980-994.		0